# INHIBRX BIOSCIENCES, INC. (INBX) FY2026 Q2 Balance Sheet

- Company: INHIBRX BIOSCIENCES, INC. (INBX)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-13, accession number 0002007919-26-000042
- Page: https://plicit.ai/financials/inbx/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/inbx-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 154,222,000 US dollars
- **Current assets**: 142,212,000 US dollars
- **Non-current assets**: 12,010,000 US dollars
- **Liabilities**: 207,199,000 US dollars
- **Current liabilities**: 28,064,000 US dollars
- **Non-current liabilities**: 179,135,000 US dollars
- **Equity**: negative 52,977,000 US dollars
- **Cash and cash equivalents**: 133,344,000 US dollars
- **Prepaid expenses and other current assets**: 8,736,000 US dollars
- **Other receivables**: 132,000 US dollars
- **Other non-current assets**: 4,769,000 US dollars
- **Operating right-of-use asset**: 4,555,000 US dollars
- **Property and equipment, net**: 2,686,000 US dollars
- **Accrued expenses**: 15,773,000 US dollars
- **Accounts payable**: 9,800,000 US dollars
- **Current portion of operating lease liability**: 2,491,000 US dollars
- **Long-term debt, net**: 176,285,000 US dollars
- **Non-current portion of operating lease liability**: 2,850,000 US dollars
- **Additional paid-in-capital**: 263,300,000 US dollars
- **Common stock, $0.0001 par value; 120,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 14,708,910 shares issued and outstanding as of June 30, 2026 and 14,577,609 shares issued and outstanding as of December 31, 2025.**: 1,000 US dollars
- **Preferred stock, $0.0001 par value; 15,000,000 shares authorized as of June 30, 2026 and December 31, 2025; no shares issued or outstanding as of June 30, 2026 and December 31, 2025.**: 0 US dollars
- **Accumulated deficit**: negative 316,278,000 US dollars

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.